2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

…, P Mease, HA Ménard, LW Moreland… - Arthritis & …, 2010 - Wiley Online Library
Objective The 1987 American College of Rheumatology (ACR; formerly, the American
Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized …

Genetics of rheumatoid arthritis contributes to biology and drug discovery

…, S Eyre, J Bowes, A Barton, N De Vries, LW Moreland… - Nature, 2014 - nature.com
A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated
variants with diverse genomic and biological data sets to provide insight into …

[HTML][HTML] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

…, MC Genovese, MC Wasko, LW Moreland… - … England Journal of …, 2000 - Mass Medical Soc
Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

[HTML][HTML] Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein

LW Moreland, SW Baumgartner… - … England Journal of …, 1997 - Mass Medical Soc
Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease…

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the …

…, EC Keystone, DE Furst, LW Moreland… - Arthritis & …, 2003 - Wiley Online Library
Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal
tumor necrosis factor α antibody, in combination with methotrexate (MTX) in patients with …

[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …

…, AF Kavanaugh, JM Kremer, LW Moreland… - Arthritis care & …, 2012 - Wiley Online Library
The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

[HTML][HTML] Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

…, NE Lane, JJ Cush, LW Moreland… - … England Journal of …, 2006 - Mass Medical Soc
Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

…, C Maclean, T Mikuls, LW Moreland… - Arthritis Care & …, 2008 - Wiley Online Library
Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and …

Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial

LW Moreland, MH Schiff, SW Baumgartner… - Annals of internal …, 1999 - acpjournals.org
Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes

…, EC Keystone, MC Wasko, LW Moreland… - … : Official Journal of …, 2002 - Wiley Online Library
Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …